Insider Selling: Capricor Therapeutics (NASDAQ:CAPR) Director Sells $1,667,397.05 in Stock

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Director Karimah Es Sabar sold 53,735 shares of the company’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $31.03, for a total transaction of $1,667,397.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Karimah Es Sabar also recently made the following trade(s):

• On Tuesday, March 31st, Karimah Es Sabar sold 61,265 shares of Capricor Therapeutics stock. The stock was sold at an average price of $30.17, for a total transaction of $1,848,365.05.

Capricor Therapeutics Price Performance

Shares of NASDAQ CAPR traded up $1.50 during midday trading on Thursday, reaching $31.62. The company’s stock had a trading volume of 346,173 shares, compared to its average volume of 1,371,751. Capricor Therapeutics, Inc. has a 12-month low of $4.30 and a 12-month high of $40.37. The firm has a 50 day moving average price of $27.04 and a 200-day moving average price of $18.74. The stock has a market capitalization of $1.82 billion, a P/E ratio of -13.99 and a beta of 0.48.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Thursday, March 12th. The biotechnology company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). On average, equities analysts predict that Capricor Therapeutics, Inc. will post -1.21 EPS for the current year.

Analyst Ratings Changes

CAPR has been the topic of a number of research analyst reports. Piper Sandler reissued an “overweight” rating and issued a $58.00 price target (up from $45.00) on shares of Capricor Therapeutics in a report on Friday, March 13th. Cantor Fitzgerald set a $62.00 price objective on shares of Capricor Therapeutics and gave the stock an “overweight” rating in a research report on Friday, March 13th. B. Riley Financial increased their target price on shares of Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a research report on Friday, March 13th. iA Financial set a $48.00 price objective on Capricor Therapeutics in a report on Wednesday, December 3rd. Finally, Maxim Group increased their target price on shares of Capricor Therapeutics from $25.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, December 4th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $46.09.

Institutional Investors Weigh In On Capricor Therapeutics

Several large investors have recently added to or reduced their stakes in CAPR. ACT Capital Management LLC bought a new stake in shares of Capricor Therapeutics during the 4th quarter valued at about $43,000. GoalVest Advisory LLC purchased a new stake in Capricor Therapeutics in the fourth quarter valued at approximately $59,000. Allworth Financial LP raised its stake in Capricor Therapeutics by 5,021.5% in the fourth quarter. Allworth Financial LP now owns 3,329 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 3,264 shares in the last quarter. Farther Finance Advisors LLC bought a new stake in Capricor Therapeutics during the third quarter valued at approximately $28,000. Finally, State of Wyoming grew its stake in Capricor Therapeutics by 76.0% in the 4th quarter. State of Wyoming now owns 4,429 shares of the biotechnology company’s stock worth $128,000 after buying an additional 1,913 shares in the last quarter. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.